The studies of urinary polyamine excretion in heart transplant patients reported in this article indicate that total urinary polyamine excretion is increased one to three days before a biopsy-proved rejection in conventionally treated patients, the acetylputrescine to N1-acetylspermidine ratio becomes elevated before rejection in cyclosporine-treated patients, and the response to elevated ATG therapy during rejection can be evaluated by monitoring urinary polyamine concentrations. We conclude that daily monitoring of urinary polyamine levels may provide a noninvasive biochemical marker that precedes rejection and which parallels the extent of T lymphocyte suppression during the course of immunosuppressive drug therapy.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Dec 1 1984|
ASJC Scopus subject areas